• US: +1-408-610-2300
  • Toll Free: +1-866-831-4085
  • Login / Register
Antibody Drug Conjugate Market Size, 2023 | Global Industry Report

Antibody Drug Conjugate (ADC) Drug Market Size Analysis, Segmentation, Industry Outlook and Forecasts, 2017 - 2023

Report ID: MN17617809  |  Published: April 2018  |  No of Pages: 110
Format: Electronic (PDF)  |  Industry: Pharmaceuticals  |  Publisher: RNCOS

The global Antibody Drug Conjugate Drug Market is estimated to develop at a substantial CAGR for the duration of the prediction. The Antibody Drug Conjugates consist of three portions; primarily a precise antibody for tie, a cytotoxic mediator intended to eradicate objective cancer cells, and a chemical linker for fastening the cytotoxic mediator to the antibody. These drug conjugates are looked upon the new-fangled stage of therapeutic mediators.

The progression in the therapeutic expertise is motivating the international market for antibody drug conjugates. Furthermore, the increasing case of cancer, growth in overweight inhabitants, and increasing elderly residents are the important motivating elements for the antibody drug conjugate market. Additionally, preclinical investigation, the growing investigation actions on antibody treatments, additional investigation on innovative medicine findings, growing exploration on oncology sicknesses, the increasing partnership among investigation organizations, biopharmaceuticals and the companies pertaining to biotechnology are empowering the market. They are projected to motivate the antibody drug conjugates market during the prediction period.

On the other hand, the greater price of techniques and the deficiency of fund may act as limitations to the progress of this market. The ADC market on the source of Type of End User could span Biotechnology Companies, Specialized Cancer Centers, Biopharmaceutical Companies, Academic Research Institutes, Hospitals, and Others. The market on the source of Type of Application could span Lymphoma, Leukemia, Multiple Myeloma, Skin Cancer, Colon Cancer, Glioblastoma, Pancreas Cancer, Prostate Cancer, Solid Tumors, Breast Cancer, Lung Cancer, Ovary Cancer, Kidney Cancer, and additional cancers.

The subdivision of Leukemia is additional separated into Chronic Lymphocytic Leukemia (CLL), Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL) and Acute Myeloid Leukemia (AML). The division of the market of Antibody Drug Conjugate Drug on the source of Type of Technology. The market divided in to- Immunomedics Technology, ImmunoGen Technology, Seattle Genetics technology and others. The division of the market of Antibody Drug Conjugate Drug on the source of Type of Product. The market divided in to Kadcyla and Adcertis. The division of the market of Antibody Drug Conjugate Drug on the source of Type. The market divided in to the types- Linker, Monoclonal Antibodies, Toxin/ Drug and others.

The statement divides market into a number of important Areas. The division done with respect to Trades in terms of intake, Profits, Market stake and Development percentage in these areas, for the duration of the prediction. The area wise division of the market done like this: North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

By the source of geography, the area of Americas ruled the international market of antibody drug conjugate due to the scientific invention, advancement in the procedures of production. The influence of nanotechnology for evolving Antibody Drug Conjugates [ADC]. Merely three antibody drug conjugates, which have received appreciation from the U.S. Food and Drug Administration [FDA] department of U.S.A. The U.S.A is the biggest market between additional nations for example Canada, Mexico and others. However, many large pharmaceutical companies are developing this technology. The proportion of achievement of developing an Antibody Drug Conjugates [ADC] is precise low and lies with actual a small number of companies. The antibody drug conjugate market of Europe is the subsequent biggest. It tracked by the area of Asia Pacific.

The area of Asia Pacific is the developing market in the international market of antibody drug conjugate. The growing alertness between customers together with increasing government inventiveness are motivating the market of antibody drug conjugate in this area. There are numerous goods underneath the development. These improvements are taking place below license arrangements.

The statement revises Trades in terms of intake of ADC Drug in the market. Particularly in the areas of North America, Europe, Asia Pacific, Latin America and Middle East & Africa. It concentrates on the topmost companies operating in these areas and the nations. With reference to Trades, Price, Profits and Market stake for respective competitor in these areas. Some of the important companies, operating in the field on international level are Oxford Bio Therapeutics, Synthon, Progenics Pharmaceuticals, Bayer HealthCare, Millennium Pharmaceuticals, Pfizer Inc., A tikor, Concortis Bio therapeutics, Roche Holding AG, Seattle Genetics, Heidelberg Pharma, Mersana Therapeutics, Astellas Pharma/Agensys, AbbVie Inc., Celldex Therapeutics, Immunomedics, Agensys, Inc., Genentech, ImmunoGen, Inc., and others.

What questions do you have? Get quick response from our industry experts. Request More information
Key questions answered in the report include
key questions
We also offers customization on reports based on specific client requirement.
Request for Customization

Choose License Type

Research Assistance

Ryan Manuel
Ryan Manuel

Research Support Specialist, USA

  1. Phone: +1-408-610-2300
  2. Toll Free: +1-866-831-4085
  3. Email: [email protected]
  • World's largest premium report database
  • Transparent pre & post sale customer engagement model
  • Unparalleled flexibility in terms of rendering services
  • Safe & secure web experience
  • 24*5 Research support service
  • 100% Secure Payments
  • Our Promise
  • 100% Service Assurance
  • Market Monitoring
  • Service Flexibility
  • 24X5 Care available